Skip to content

Trial Objectives


People with eosinophilic granulomatosis with polyangiitis (EGPA) are needed for the OCEAN clinical trial. The study compares two medications:  mepolizumab (NUCALA), which is administered by an injection once a month, and depemokimab, an investigational medication that is injected twice a year. Researchers want to understand if depemokimab is as safe and effective as mepolizumab. Volunteers will receive a blood draw and will be randomly assigned to receive an injection of one of the two medications.

Who Can Participate


Adults with EGPA that has worsened or returned after previous treatment and are taking a corticosteroid or immunosuppressant

Age: 18+ Gender Any

Estimated Time Commitment


Once a month visits for approximately 15 months

Payment & Reimbursement


Payment Provided

Travel Reimbursement Available

Trial Contact


For more information, contact:

Allen Stevens
303.398.1268

Request More Information

Trial Location


National Jewish Main Campus, Denver, CO

Trial Sponsors


GSK

Principal Investigators

Michael E. Wechsler

Michael E. Wechsler, MD, MMSc

Co-Investigators

Vamsi P. Guntur

Vamsi P. Guntur, MD, MSc

Request more Information

By completing this form, you agree to learn more about this study and see if you qualify.

I would also like to receive periodic emails with health information, news and clinical research updates from National Jewish Health required